J. David Leander

Skagit Neuropharm 
"J. Leander"
Mean distance: 17.16 (cluster 19)
Cross-listing: Neurotree

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rodriguez MM, Overshiner C, Leander JD, et al. (2017) Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder. Frontiers in Psychiatry. 8: 89
Wolff MC, Leander JD. (1997) Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. European Journal of Pharmacology. 340: 217-20
Wolff MC, Leander JD. (1997) Differentiation of 5-HT1A receptor ligands by drug discrimination. European Journal of Pharmacology. 333: 113-22
Benvenga MJ, Ornstein PL, Leander JD. (1995) Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons. The Journal of Pharmacology and Experimental Therapeutics. 275: 164-70
Benvenga MJ, Leander JD. (1995) Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology. 119: 133-8
Wolff MC, Leander JD. (1994) Antiemetic effects of 5-HT1A agonists in the pigeon. Pharmacology, Biochemistry, and Behavior. 49: 385-91
Shaw WN, Mitch CH, Leander JD, et al. (1991) The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat. International Journal of Obesity. 15: 387-95
Leander JD, Lawson RR, Robertson DW. (1988) Anticonvulsant effects of a novel aminobenzamide (LY201116) in mice. Neuropharmacology. 27: 623-8
Leander JD. (1988) Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. European Journal of Pharmacology. 151: 457-61
Leander JD, Gesellchen PD, Mendelsohn LG. (1988) Opioid antinociceptive effects of delta-receptor antagonists. Pharmacology, Biochemistry, and Behavior. 29: 351-5
See more...